Company Filing History:
Years Active: 2001-2004
Title: Sergei L Kiselev: Innovator in Cancer Research
Introduction
Sergei L Kiselev is a prominent inventor based in Moscow, Russia. He has made significant contributions to the field of cancer research, particularly in the identification of genes that inhibit tumor growth and induce apoptosis in cancer cells. His work has led to the development of innovative methods and polypeptides that hold promise for cancer therapy.
Latest Patents
Sergei L Kiselev holds 2 patents related to tumor growth inhibition and apoptosis-associated genes. His latest patents include the identification of mouse and human genes that inhibit tumor growth and induce apoptosis in cancer cells. One of the key inventions concerns the nucleotide sequence of a tumor-inhibiting gene known as tag7, along with the amino acid sequence of the polypeptide encoded by this gene. The patents also provide isolated nucleic acid molecules comprising tag7 polynucleotides, as well as methods for producing tag7 polypeptides and antibodies that specifically bind to the tag7 polypeptide. These inventions are crucial for developing methods of cancer therapy using tag7 nucleic acid molecules and polypeptides.
Career Highlights
Sergei L Kiselev is currently associated with Boehringer Ingelheim International GmbH, where he continues to advance his research in cancer biology. His work has been instrumental in paving the way for new therapeutic approaches to combat cancer.
Collaborations
Some of his notable coworkers include Georgii P Georgiev and Egor B Prokhorchouk, who have collaborated with him on various research projects.
Conclusion
Sergei L Kiselev's innovative work in cancer research exemplifies the impact of scientific inquiry on medical advancements. His contributions to the understanding of tumor growth inhibition and apoptosis are paving the way for future therapies in oncology.